Medicine and Dentistry
Acute Kidney Injury
11%
Anesthesiologist
5%
Antiretroviral Therapy
28%
Arm
8%
Biological Product
6%
Cell Count
8%
Chlamydiae
5%
Chronic Kidney Disease
10%
Clinical Significance
6%
Cohort Analysis
12%
Cohort Study
8%
Cost-Effectiveness Analysis
7%
Darunavir Plus Ritonavir
5%
Disease Activity
16%
Disease Activity Score
20%
Disease Exacerbation
7%
Disease Modifying Antirheumatic Drug
20%
Disease-Modifying Antirheumatic Drug
10%
Diseases
25%
Efavirenz
13%
Glomerular Filtration Rate
15%
Hazard Ratio
9%
Health Assessment Questionnaire
10%
Health Care Cost
10%
Human Immunodeficiency Virus
71%
Infection
7%
Inflammatory Arthritis
83%
Intensive Care
11%
Kidney Function
13%
Mental Function
6%
Mental Health
9%
Monotherapy
12%
Nephropathy
11%
Nonnucleoside Reverse Transcriptase Inhibitor
6%
Observational Study
6%
Primary Health Care
6%
Prospective Cohort Study
5%
Prostate Cancer
11%
Quality of Life
26%
Randomized Controlled Trial
28%
Rheumatoid Arthritis
83%
Rheumatology
7%
Short Form 36
16%
Spontaneous Remission
5%
Systematic Review
23%
Tenofovir
8%
TNF Inhibitor
28%
Treatment-Resistant Schizophrenia
5%
Vitamin D
6%
Zidovudine
5%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Kidney Failure
11%
Alkaline Phosphatase
5%
Anakinra
5%
Antiphospholipid Syndrome
5%
Bacterial Arthritis
5%
Base
5%
Biological Product
11%
Cancer Prognosis
5%
Cardiovascular Risk
7%
Chronic Kidney Failure
17%
Ciclosporin
9%
Clinical Trial
6%
Cohort Study
9%
Combination Therapy
7%
Comorbidity
5%
Darunavir Plus Ritonavir
5%
Disease Activity
19%
Disease Activity Score
15%
Disease Exacerbation
12%
Disease Modifying Antirheumatic Drug
23%
Diseases
22%
Efavirenz
14%
Emtricitabine
5%
Glucocorticoid
8%
HIV
60%
Hypovitaminosis D
5%
Immune Deficiency
5%
Inflammatory Arthritis
100%
Ischemic Heart Disease
5%
Kidney Disease
11%
Lamivudine
5%
Methotrexate
27%
Monotherapy
16%
Myositis
11%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Observational Study
6%
Placebo
15%
Population Study
5%
Prostate Cancer
11%
Psoriatic Arthritis
5%
Randomized Controlled Trial
33%
Remission
23%
Rheumatoid Arthritis
100%
RNA Directed DNA Polymerase
5%
Tenofovir Disoproxil
5%
Tumor Necrosis
5%
Tumor Necrosis Factor Inhibitor
32%
Vitamin D
6%
Vitamin D Deficiency
5%
Zidovudine
5%
Nursing and Health Professions
Antiphospholipid Syndrome
5%
Antiretroviral Therapy
5%
Bacterial Arthritis
5%
Biological Product
10%
Clinical Effectiveness
5%
Combination Therapy
5%
Confidence Interval
9%
Correlation Coefficient
5%
Cost Effectiveness Analysis
9%
DAS28
6%
Disease Activity
20%
Disease Activity Score
21%
Disease Exacerbation
12%
Disease Modifying Antirheumatic Drug
18%
Diseases
9%
Economic Evaluation
6%
Estimated Glomerular Filtration Rate
5%
General Practice
5%
Health Assessment Questionnaire
11%
Human immunodeficiency virus
15%
Inflammatory Arthritis
98%
Intensive Care
12%
Kidney Disease
5%
Mental Health
7%
Methotrexate
5%
Monotherapy
6%
Myositis
5%
Practice Guideline
8%
Quality of Life
19%
Remission
33%
Rheumatoid Arthritis
98%
Short Form 36
6%
Social Support
5%
Systematic Review
23%
Treatment Response
7%
Tumor Necrosis
5%
Tumor Necrosis Factor Inhibitor
24%
Urethritis
5%
Zidovudine
5%
